Doxycycline Dosing for H. pylori Infection
Doxycycline 100 mg twice daily for 14 days is the recommended dose when used in bismuth-containing quadruple therapy for H. pylori eradication.
Standard Dosing Regimen
The established doxycycline dose for H. pylori treatment is 100 mg twice daily (BID) as part of a quadruple therapy regimen 1. This dosing appears consistently across major international guidelines (Toronto Consensus, Maastricht V/Florence, and American College of Gastroenterology).
Complete Quadruple Therapy Regimen:
- Doxycycline: 100 mg BID
- PPI: Standard dose BID (e.g., omeprazole 20 mg, esomeprazole 20 mg, rabeprazole 20 mg)
- Bismuth: QID (dose varies by formulation - bismuth subsalicylate 262 mg × 2 tablets or colloidal bismuth subcitrate 120 mg)
- Metronidazole: 400-500 mg TID-QID
- Duration: 14 days 1
Clinical Context and Evidence
Doxycycline serves as a tetracycline alternative in H. pylori regimens, particularly useful when standard tetracycline is unavailable or in patients with specific contraindications. Recent research demonstrates:
- First-line therapy: A 2019 pilot study showed 89.8% ITT eradication rate with bismuth-rabeprazole-amoxicillin-doxycycline (RADB) regimen using doxycycline 100 mg BID for 14 days 2
- Dual therapy option: Emerging data from 2026 suggests vonoprazan-doxycycline dual therapy (100 mg BID) achieves 76-87% eradication rates, though this falls below the preferred 80% threshold for first-line therapy 3, 4
Higher Dose Considerations
A 2015 study explored doxycycline 200 mg BID in quadruple therapy, achieving 92.1% eradication (ITT), compared to 88.5% with 100 mg BID 5. However, this higher dose has not been adopted in major guidelines and requires further validation.
Important Clinical Caveats
Do not use doxycycline as monotherapy or simple dual therapy as first-line treatment - the evidence shows suboptimal eradication rates (76-79% ITT) 3, 4. Reserve dual therapy for:
- Patients with penicillin allergy who cannot tolerate standard quadruple therapy
- Simplified regimens in specific clinical scenarios with informed consent about lower efficacy
Resistance considerations: Unlike clarithromycin and levofloxacin, tetracycline/doxycycline resistance remains rare, making it a valuable component when other antibiotics have failed 1.
Treatment duration: All major guidelines converge on 14 days as the optimal duration for first-line therapy, though 10 days may be acceptable if proven locally effective 1.
Position in Treatment Algorithm
According to the 2021 AGA expert review, doxycycline-containing regimens are not standard first-line therapy 6. The preferred first-line options remain:
- Bismuth quadruple therapy with tetracycline (not doxycycline)
- Concomitant non-bismuth quadruple therapy
- High-dose dual PPI-amoxicillin therapy
Doxycycline becomes relevant when:
- Tetracycline is unavailable
- Patient has specific contraindications to standard regimens
- As part of salvage therapy after first-line failure
The FDA-approved doxycycline dosing for general infections (100 mg every 12 hours after 200 mg loading dose) aligns with the H. pylori regimen dosing 7, though H. pylori treatment is an off-label use requiring the full quadruple therapy context.